Betta Pharmaceuticals Co., Ltd.
Quick facts
| Founded | 2003 |
|---|
Marketed products
- Icotinib plus WBRT · Oncology
Icotinib is an EGFR tyrosine kinase inhibitor that blocks epidermal growth factor receptor signaling in cancer cells, combined with whole-brain radiotherapy (WBRT) to treat brain metastases. - Maintenance icotinib · Oncology
Icotinib is a small-molecule tyrosine kinase inhibitor that selectively blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation. - Sequential and maintenance icotinib · Oncology
Icotinib is a small-molecule tyrosine kinase inhibitor that selectively blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation. - Sequential Icotinib Plus Chemotherapy · Oncology
Icotinib is an EGFR tyrosine kinase inhibitor that blocks epidermal growth factor receptor signaling, used sequentially with chemotherapy to treat EGFR-mutant lung cancer.
Phase 3 pipeline
- BPI-16350 · Oncology
BPI-16350 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.
Phase 2 pipeline
- 2-year treatment with icotinib
- Chemoradiotherapy · Other
- D-0316 Capsule
D-0316 Capsule is a small molecule that targets the molecular target. - Higher dose icotinib
- Icotinib Hydrochloride Tablets · Oncology
Tyrosine kinase inhibitor - Icotinib with concurrent radiotherapy · Oncology
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor - MCLA-129
- Routine dose icotinib
- X-396 Capsule
Phase 1 pipeline
- 1.0% Icotinib hydrochloride cream
- [14C]D-0316 suspension
- BPB-101
- BPI-15086
- BPI-21668
- BPI-28592
- BPI-361175
- BPI-371153
- BPI-421286
- BPI-442096
- BPI-452080
- BPI-460372
- BPI-572270
- BPI-9016M
- Ensartinib with fed or fasting
- MRX2843
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: